Skip to Content

Steris PLC

STE: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$641.00HjxrztLdddhbncw

Steris Starts Fiscal Year on the Right Track With Strong Sales Growth and Record (Adjusted) EPS

Narrow-moat Steris had a good start to its 2022 fiscal year, its first as a combined company with Cantel. We are maintaining our $189 fair value estimate, and we see shares as moderately overvalued after the stock’s 12% run since May.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of STE so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center